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Dominant mutations in Cu/Zn-superoxide dismutase (SOD1) gene have been shown to
cause a familial form of amyotrophic lateral sclerosis (SOD1-ALS). A major pathological
hallmark of this disease is abnormal accumulation of mutant SOD1 oligomers in the
affected spinal motor neurons. While no effective therapeutics for SOD1-ALS is currently
available, SOD1 oligomerization will be a good target for developing cures of this disease.
Recently, we have reproduced the formation of SOD1 oligomers abnormally cross-linked
via disulfide bonds in a test tube. Using our in vitro model of SOD1 oligomerization,
therefore, we screened 640 FDA-approved drugs for inhibiting the oligomerization of
SOD1 proteins, and three effective classes of chemical compounds were identified.
Those hit compounds will provide valuable information on the chemical structures for
developing a novel drug candidate suppressing the abnormal oligomerization of mutant
SOD1 and possibly curing the disease.
Keywords: Cu/Zn-superoxide dismutase, amyotrophic lateral sclerosis, protein misfolding, protein aggregation,
drug screening
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by the
progressive loss of motor neurons, leading to muscle atrophy and total paralysis. While increasing
numbers of causative genes for a familial form of ALS have been identified,∼90% of the ALS cases
are sporadic, and the pathomechanism still remains largely unknown (Andersen and Al-Chalabi,
2011; Renton et al., 2014). Also, no clinically approved drug is available for ALS except Riluzole,
which can extend the median survival by only a few months (Genc and Ozdinler, 2014); therefore,
a great need for new ALS therapeutics is obvious. Despite this, it remains obscure what triggers
sporadic ALS, hampering the identification of molecular target(s) for the development of drugs to
ameliorate and eventually prevent this devastating disease.
As mentioned, several genes responsible for a familial form of ALS cases have been identified
(Abel et al., 2012), among which mutations in Cu/Zn-superoxide dismutase (SOD1) gene are
the most common cause (about 20%) of familial ALS cases (SOD1-ALS; Rosen et al., 1993). A
pathological hallmark observed in SOD1-ALS cases is abnormal accumulation of mutant SOD1
proteins in the affected motor neurons as inclusions (Bruijn et al., 1998). Furthermore, in vivo
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as well as in vitro experiments have shown that pathogenic
mutations trigger the misfolding of SOD1 proteins and then
lead to the formation of insoluble SOD1 oligomers/aggregates
(reviewed in Furukawa, 2012). Misfolding of SOD1 proteins is
thus one of the promising targets to develop therapeutics of
SOD1-ALS cases.
SOD1 is an antioxidant enzyme detoxifying superoxide
radicals and becomes enzymatically active by binding copper
and zinc ions and forming a highly conserved intramolecular
disulfide bond (McCord and Fridovich, 1969; Furukawa et al.,
2004). Given that these post-translational processes are known to
stabilize the native conformation of SOD1 proteins, pathogenic
mutations are considered to decrease the conformational stability
of SOD1 by compromising binding of the metal ions and/or
formation of the disulfide bond (Furukawa andO’Halloran, 2005;
Rodriguez et al., 2005). Regardless of the presence or absence of
metal binding and/or disulfide formation, furthermore, most of
pathogenic mutations are shown to decrease structural stability
of SOD1 proteins (Furukawa and O’Halloran, 2005; Rodriguez
et al., 2005); therefore, the decrease in the structural stability
of SOD1 is considered to trigger the misfolding into a toxic
conformer(s). It is thus well expected that misfolding of SOD1
into oligomers and aggregates can be suppressed by stabilizing
the native conformation of SOD1.
A native form of SOD1 is a homodimer, and the mutation-
induced monomerization of SOD1 has been suggested to trigger
the aggregation (Rakhit et al., 2004). Actually, introduction
of a disulfide bond between the SOD1 subunits by either
genetic engineering (Ray et al., 2004) or chemical cross-linkers
(Auclair et al., 2010) has been shown to forcedly stabilize the
SOD1 dimeric structure. The coordination of a metallo-complex,
cisplatin, at the dimer interface was also shown to be effective
to suppressing the SOD1 oligomerization in the cultured cells
as well as in a test tube (Banci et al., 2012). To more reversibly
stabilize the natively dimeric SOD1 conformation, small drugs
that can bind at the dimer interface were identified by extensive
in silico screening of ∼1.5 million compounds (Ray et al., 2005;
Nowak et al., 2010). These drugs were found to protect A4V-
mutant SOD1 from chemical unfolding induced by guanidine
hydrochloride (Gdn) and also significantly slow the aggregation
(Ray et al., 2005; Nowak et al., 2010). The binding site of those
drugs in SOD1, however, needs to be experimentally confirmed in
more detail; actually, some of the drugs were shown to bind at the
alternative site other than the dimer interface (Antonyuk et al.,
2010; Wright et al., 2013). Further studies will also be required
to confirm the reproducibility on the stabilizing effects of those
drugs on SOD1 (Wright et al., 2013), and in vivo efficacy of those
dimer-stabilizing drugs remains to be tested. To identify drugs
that can reduce the intracellular aggregation of mutant SOD1,
moreover, high throughput screening of∼50,000 small molecules
has been performed in the cultured cells expressingmutant SOD1
fused with a fluorescent protein, GFP (Benmohamed et al., 2011).
Aggregation properties of SOD1 proteins have, however, been
reported to be affected by the fusion with a GFP tag (Stevens et al.,
2010). While efforts have been made to stabilize mutant SOD1 in
a drug-based approach, no drugs are promising for animal and
clinical trials, and we hence still need to explore and test more
numbers of potent inhibitors for aggregation/oligomerization of
mutant SOD1 proteins.
Here, we have performed screening of FDA-approved drugs
in our experimental setup reproducing SOD1 oligomerization
in vitro and identified drugs that can suppress the formation
of insoluble SOD1 oligomers. Previously, we have shown that
pathogenic SOD1 proteins form SDS-resistant oligomers
crosslinked via disulfide bonds in the spinal cords of
symptomatic ALS-model mice expressing mutant SOD1
(Furukawa et al., 2006). We also recently reported that formation
of disulfide-crosslinked oligomers was reproduced in a test
tube by incubation of metal-deficient (apo) SOD1 with the
disulfide bond (apo-SOD1S-S) in the presence of a denaturant
(Toichi et al., 2013). The hit compounds in a library of
FDA-approved drugs efficiently suppressed the formation of
insoluble SOD1 oligomers crosslinked via disulfide bonds. The
structural/chemical information on those compounds will hence
be useful to design a pharmaceutical drug for SOD1-ALS with
aggregation-inhibiting properties.
MATERIALS AND METHODS
Preparation of Proteins
Expression and purification of SOD1 with G37R mutation were
performed as described previously (Furukawa et al., 2016).
Briefly, SOD1(G37R) was expressed in E. coli SHuﬄeTM (New
England BioLabs) as a fusion protein with an N-terminal 6x
His tag and was purified with Ni2+-affinity chromatography
using HisTrap HP column (1mL, GE Healthcare). The purified
proteins were dialyzed against 50mM sodium acetate, 100mM
NaCl, and 10mM EDTA at pH 4.0, which removed metal
ions bound to the His-tagged SOD1(G37R). After proteolytic
cleavage of the His tag with thrombin, the demetallated and
untagged SOD1(G37R) was further purified with gel-filtration
chromatography using Cosmosil 5Diol-300-II column (nacalai
tesque). Presence of the intramolecular disulfide bond in SOD1
was confirmed based upon its distinct electrophoretic mobility
in non-reducing SDS-PAGE (Toichi et al., 2013). HTTEX1(42Q)
were prepared as described previously (Mitomi et al., 2012).
Concentrations of SOD1 and HTTEX1(42Q) proteins were
spectroscopically determined from the absorbance at 280 nm
in the presence of 6M guanidine hydrochloride (Gdn) by
using 5625 and 42,860 cm−1M−1 as an extinction coefficient,
respectively.
Screening of Drugs Inhibiting the SOD1
Oligomerization
To examine effects of drugs on the abnormal oligomerization of
SOD1 in vitro, apo-SOD1(G37R)S-S (20µM, 150µL) in a buffer
at pH 7.4 containing 100mM Na-Pi, 100mM NaCl and 5mM
EDTA (NNE buffer) with 1M Gdn was first prepared in each
well of a 96-well-plate. Then, 1.5µL of a 2.0 g/L stock solution
of drugs in DMSO was added to the protein sample solution in
a well of the plate (the final concentration of drugs tested was
20µg/mL). In this study, we have examined 640 drugs in the
FDA approved drug library (#BML-2841J-0100, Japanese version,
Enzo Life Science). The oligomerization reaction was started by
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shaking the samples with a POM ball (3/32 inch, SANPLATEC)
in a plate shaker (MBR-022UP, TAITEC) at 1200 rpm, 37◦C
and monitored by the increase of solution turbidity (absorbance
increase at 350 nm). After 12 h of agitation, the samples were
collected and ultracentrifuged at 110,000 × g for 15min. to
obtain soluble supernatant and insoluble pellet separately. After
removing Gdn in the soluble supernatant with PAGE Clean Up
Kit (nacalai tesque), the proteins in both fractions were analyzed
by non-reducing SDS-PAGE.
Electrophoresis
To protect free thiols from aberrant oxidation during
electrophoresis, proteins were reacted with a thiol-specific
modifier, iodoacetamide (IA); the samples were first dissolved
in a buffer at pH 8.0 containing 100mM Na-Pi, 2% SDS, and
100mM IA and then incubated at 37◦C for an hour. Followed
by the addition of an SDS-PAGE sample buffer without any
reductants, the protein samples were boiled at 100◦C for 5min.
and then loaded on a 12.5% resolving polyacrylamide gel with a
5% stacking gel. After electrophoresis, the protein bands on a gel
were visualized by Coomassie Brilliant Blue.
Differential Scanning Calorimetry
Effects of drugs on the thermal stability of SOD1 were examined
by differential scanning calorimetry (DSC) using MicroCal VP-
DSC (GE Healthcare). Apo-SOD1(G37R)S-S (0.3 g/L; ca. 20µM)
in the NNE buffer with or without a drug (20µg/mL) was
first degassed using ThermoVac (GE Healthcare) at 20◦C for
5min., and then the thermograms were obtained by increasing
temperature from 15◦ to 75◦C at a scan rate of 1.0◦C/min.
Baselines were collected by using the NNE buffer containing
corresponding drugs and DMSO. The thermograms of protein
samples were corrected with the baselines and then normalized
by protein concentrations.
MALDI-TOF Mass Spectrometry
To map the disulfide bond in SOD1, the limited proteolysis
followed by the peptide mapping was performed. As described,
apo-SOD1(G37R)S-S was agitated in the presence of 1MGdn for
2 h at 37◦C, and a soluble fraction of the sample was collected
by ultracentrifugation at 110,000 × g for 15min. Proteins in the
soluble fraction were first precipitated using PAGE Clean Up Kit
and then redissolved in the NNE buffer containing 100mM IA
and 6MGdn. After incubation at 37◦C for an hour, by which free
thiolate groups were alkylated and thus protected, the buffer was
exchanged to 100mM Na-Pi at pH 8.0 by using a ZebaTM Spin
Desalting Column (Thermo). SOD1 proteins (48µg) collected by
the spin column were treated with 0.24µg of porcine pancreas
trypsin in a sequencing grade (Wako) and incubated at 37◦C for
16 h. After addition of 0.1% trifluoroacetic acid and 6MGdn, the
trypsinized samples were desalted with ZipTip C18 (Millipore)
and then spotted on a MALDI target plate with human ACTH
(18–39) (m/z, 2466.6; Wako) and bovine pancreas insulin (m/z,
5734.5; nacalai tesque) as internal standards and with α-cyano-4-
hydroxycinnamic acid (Wako) as a matrix. Spectra were obtained
using UltraflexTM (Bruker Daltonics) in linear mode, and mass
peaks were assigned using MS Bridge (University of California,
San Francisco, CA).
RESULTS AND DISCUSSION
Oligomerization of Mutant SOD1 in the
Destabilizing Conditions
It has been reported that agitation of apo-SOD1S-S forms
insoluble aggregates in the presence of 1MGdn (Chattopadhyay
et al., 2008; Toichi et al., 2013). As shown in Figure 1A, we
confirmed the increase of solution turbidity by agitation of
20µM apo-SOD1S-S with a pathogenic mutation, G37R [apo-
SOD1(G37R)S-S], at 37◦C, indicating the formation of insoluble
aggregates. In contrast, the agitation of apo-SOD1(G37R)S-S in
the absence of Gdn did not result in the formation of insoluble
aggregates (Figure 1A). To further confirm the insolubilization
of apo-SOD1(G37R)S-S by its agitation in the presence of
1MGdn at 37◦C, the samples were fractionated into soluble
supernatant and insoluble pellets by ultracentrifugation and
analyzed by non-reducing SDS-PAGE (Figure 1B). Increase in
the solution turbidity was confirmed to associate with the
formation of insoluble SOD1 oligomers that were sensitive to
the reducing reagent, dithiothreitol (DTT; Figure 1C). Namely,
in the current reaction conditions, apo-SOD1(G37R)S-S was
converted to the insoluble SOD1 oligomers crosslinked via
disulfide bonds (S-S oligomers).
We also noted that, before the formation of S-S oligomers, the
electrophoretic mobility of SOD1 under the denatured condition
(i.e., in SDS-PAGE) became slightly retarded and blurred
(compare the bands in the soluble fractions at 240 vs. 0min. in
Figure 1B). Treatment of the samples with DTT again collapsed
those distinct SOD1 bands into a single band corresponding to
the disulfide-reduced SOD1 (SOD1SH; Figure 1C). Consistent
with our previous findings (Toichi et al., 2013), these results
indicate that the disulfide shuﬄing occurs first within a SOD1
molecule and then between the molecules to form the insoluble
S-S oligomers. Given that accumulation of the insoluble S-S
oligomers is known as a pathological hallmark observed in the
spinal cords of the affectedmice expressing mutant human SOD1
proteins (Deng et al., 2006; Furukawa et al., 2006), we attempted
to seek small molecules that can inhibit the formation of insoluble
S-S oligomers.
Screening of Drugs for the Activity to
Suppress the Oligomerization of Mutant
SOD1
To facilitate the transfer of possible drug candidates to the
clinical trials, we chose a library of 640 drugs, which have been
already approved by the U.S. Food and Drug Administration
(FDA). Twenty micrometer of apo-SOD1(G37R)S-S in the NNE
buffer containing 1MGdn were mixed with a drug in the
final concentration of 20µg/mL and shaken at 1200 rpm, 37◦C.
While, in the absence of any drugs, the solution turbidity
(absorbance at 350 nm) of apo-SOD1(G37R)S-S was around
0.2 at 500min after agitation (Figure 1A), drugs showing the
turbidity of <0.02 at 500min after agitation were chosen in this
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FIGURE 1 | Formation of insoluble apo-SOD1(G37R)S-S oligomers by structural destabilization. (A) Formation kinetics of insoluble aggregates from 20µM
apo-SOD1(G37R)S-S was monitored by the increase of solution turbidity (absorbance at 350 nm) in the absence (open circles) and presence (filled circles) of 1MGdn.
Experiments were repeated more than three times to estimate error bars (standard deviation). (B,C) During the aggregation of apo-SOD1(G37R)S-S shown in (A),
aliquots were taken from the sample solution at the indicated time, fractionated into soluble supernatant (s), and insoluble pellet (p) by ultracentrifugation and then
analyzed by (B) non-reducing SDS-PAGE and (C) reducing SDS-PAGE after treatment of the samples with DTT. The bands corresponding to SOD1 proteins with and
without the canonical disulfide bond are indicated by open and filled arrows, respectively.
study as “hit” compounds probably suppressing the formation
of insoluble SOD1 aggregates. In the library of FDA-approved
drugs, six compounds were found to almost completely suppress
the increase of solution turbidities: simvastatin (Figure 2A),
lovastatin (Figure 2B), mevastatin (Figure 2C), miltefosine
(Figure 2E), alfacalcidol (Figure 3A), calcidiol (Figure 3B), and
calcitriol (Figure 3C). Inhibitory effects of these drugs on the
formation of insoluble aggregates were also confirmed in the final
concentration of 10µg/mL (data not shown). Based upon the
chemical structure, those hit compounds can be categorized into
three groups as follows.
The first group contains simvastatin, lovastatin, and
mevastatin, all of which are cholesterol-lowering agents by
inhibiting the rate-limiting enzyme, HMG-CoA reductase, in
cholesterol biosynthesis with quite similar chemical structures
composed of hexahydronaphthalene, heptanoic acid lactone,
and butanoate groups (Figures 2A–C). In the absence of any
drugs, apo-SOD1(G37R)S-S formed insoluble S-S oligomers
with no SOD1 proteins in the soluble fraction (Figure 4,
no drugs), resulting in the increase of solution turbidity. By
addition of those three statins, all SOD1 proteins remained
soluble (Figure 4), corroborating the suppression of turbidity
increase. Notably, the library of FDA-approved drugs tested in
this study contains another statin with the similar structure,
pravastatin lactone, which was, however, found to have no effects
on the turbidity increase of the apo-SOD1(G37R)S-S sample
(Figure 2D) and show reduced ability to suppress the formation
of insoluble S-S oligomers (Figure 4). Other statins in the library
(nystatin, cilastatin, cerivastatin, and fluvastatin), which have
quite distinct chemical structures from e.g., simvastatin, were
also tested but exhibited no effects on the SOD1 aggregation in
vitro (data not shown). Further investigation will be required
to describe in vitro efficacy of those statins as an inhibitor
for SOD1 aggregation, but lovastatin and pravastatin lactone
differ in only one structural respect: a substituent in the
hexahydronaphthalene group is a methyl group in lovastatin
but a hydroxyl group in pravastatin lactone (Figures 2B,D).
Hydrophobicity in the hexahydronaphthalene group would
hence be necessary for inhibition of the SOD1 oligomerization
(vide infra).
The second group includes alfacalcidol, calcidiol, and
calcitriol (Figures 3A–C), all of which are derivatives of vitamin
D. Actually, calciferol (vitamin D2) and cholecalciferol (vitamin
D3) were not included in the FDA-approved drug library
used in this study but effectively suppressed the increase
of the solution turbidity in the apo-SOD1(G37R)S-S sample
(Figures 3E,F). The drug library in this study has another
vitaminD derivative, calcipotriol, which was, however, ineffective
to the suppression of the solution turbidity increase in the
apo-SOD1(G37R)S-S sample (Figure 3D). Furthermore, SOD1
proteins were confirmed to remain soluble without any insoluble
SOD1 aggregates/oligomers by adding either one of vitamin
D derivatives examined here except calcipotriol (Figure 4).
While no obvious correlation was confirmed between the
chemical structures and the efficacy to suppress the formation
of insoluble SOD1 oligomers, it is interesting to note that
the water solubility of calcipotriol is presumably higher than
those of the other vitamin D derivatives. More precisely, as
summarized in Table 1, the water solubility of the vitamin
D derivatives that are effective to the inhibition of SOD1
aggregation ranges from 0.00038 g/L (1.0µM, cholecalciferol)
to 0.0067 g/L (16µM, calcitriol); in contrast, calcipotriol is
expected to have 0.014 g/L (33µM) of the water solubility.
Actually, the water solubility of pravastatin lactone (0.024 g/L,
59µM), which was unable to suppress the turbidity increase
(Figure 2D), is comparable to that of calcipotriol and is
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FIGURE 2 | Statins and miltefosine as potent inhibitors for the formation of insoluble apo-SOD1(G37R)S-S aggregates. (A–E) The turbidity increase of
20µM apo-SOD1(G37R)S-S in the presence of 1MGdn is shown in the presence of the following compounds (red filled circles): (A) simvastatin, (B) lovastatin, (C)
mevastatin, (D) pravastatin lactone, and (E) miltefosine. In each panel, the aggregation kinetics without any drugs was shown as gray filled circles. The kinetics was
monitored by changes in the solution turbidity (the absorbance at 350 nm), and the final concentration of drugs added was 20µg/mL. Experiments were repeated
more than three times to estimate error bars (standard deviation). Structures of the chemical compounds were also shown below the panels.
significantly higher than those of the other statins that can
inhibit the SOD1 aggregation (0.00077–0.0048 g/L; Table 1).
Collectively, therefore, the hydrophobicity of the drugs would
be an important factor to modulate the efficacy for inhibiting
the oligomerization of SOD1. We further speculate that apo-
SOD1(G37R)S-S exposes its hydrophobic interior upon structural
destabilization and thereby forms abnormal oligomers. The
drugs with significant hydrophobicity might hence inhibit such
abnormal oligomerization by interacting with the hydrophobic
interior of SOD1.
Miltefosine, a phospholipid antimicrobial drug, belongs to the
last group of our hit compounds (Figure 2E). In the presence
of miltefosine, the turbidity increase of apo-SOD1(G37R)S-S
was almost completely suppressed (Figure 2E), and no insoluble
SOD1 oligomers were detected (Figure 4). The water solubility
of miltefosine has been calculated as a very limited value
(0.00022 g/L, 0.5µM, Table 1). Actually, however, miltefosine
(Cayman Chemical No. 63280) was soluble in water (2.5 g/L)
probably by forming micelles because of its hydrophobic alkane
chain with hydrophilic phosphate and amine groups. We thus
suppose that the hydrophobic part of miltefosine plays a role
in the interaction with misfolded SOD1 and the inhibition of
abnormal oligomerization.
Specificity of the Drugs to Suppress
Protein Aggregation/Oligomerization
Not all drugs with significant hydrophobicity (or limited
water solubility) were potent against inhibition of SOD1
oligomerization; for example, cerivastatin and fluvastatin have
comparable water solubility (ca. 4 × 10−3 g/L) to that of
simvastatin and mevastatin but did not affect the aggregation
kinetics of apo-SOD1(G37R)S-S (data not shown). Accordingly,
the chemical structures of our hit compounds will have specific
interactions with apo-SOD1(G37R)S-S to inhibit the formation
of insoluble oligomers.
In addition to the formation of S-S oligomers, we have
previously shown that reduction of the disulfide bond in
apo-SOD1 triggers the formation of insoluble aggregates
with amyloid-like fibrillar morphologies (Furukawa et al.,
2008). As shown in Figure 5A (no drugs), the disulfide-
reduced form of apo-SOD1 with G37R mutation [apo-
SOD1(G37R)SH] was confirmed to form insoluble aggregates by
shaking at 37◦C overnight. We have then chosen simvastatin,
alfacalcidol, and miltefosine as representatives of the three
groups mentioned above and tested their efficacy to suppress the
formation of amyloid-like insoluble aggregates derived from apo-
SOD1(G37R)SH. Almost all fractions of apo-SOD1(G37R)SH,
however, became insoluble even in the presence of those three
representative drugs (Figure 5A). Furthermore, in order to test
if inhibitory effects of those drugs on the protein aggregation
are limited to SOD1, we examined the aggregation of huntingtin
with an elongated polyQ tract, which is a pathological hallmark
of Huntington disease. As shown in Figure 5B, the translation
product of exon 1 in the huntingtin gene with 42 consecutive
glutamines [HTTEX1(42Q)] formed insoluble aggregates in a
sigmoidal kinetics; however, no inhibitory effects of the drugs on
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FIGURE 3 | Vitamin D derivatives as potent inhibitors for the formation of insoluble apo-SOD1(G37R)S-S aggregates. (A–F) The turbidity increase of 20µM
apo-SOD1(G37R)S-S in the presence of 1MGdn is shown in the presence of the following compounds (red filled circles): (A) alfacalcidol, (B) calcidol, (C) calcitriol, (D)
calcipotriol, (E) calciferol, and (F) cholecalciferol. In each panel, the aggregation kinetics without any drugs was shown as gray filled circles. The kinetics was
monitored by changes in the solution turbidity (the absorbance at 350 nm), and the final concentration of drugs added was 20µg/mL. Experiments were repeated
more than three times to estimate error bars (standard deviation). Structures of the chemical compounds were also shown below the panels.
the aggregation of HTTEX1(42Q) were confirmed. Furthermore,
the three representative drugs inhibited the turbidity increase
in the aggregation of apo-SOD1S-S with the other ALS-causing
mutation, G85R (data not shown). These results thus show
that the drugs (simvastatin, alfacalcidol, and miltefosine) can
effectively and also specifically suppress the formation of
insoluble S-S oligomers derived from apo-SOD1S-S proteins.
Nonetheless, it remains obscure how those drugs interact with
SOD1 to keep it soluble.
The Drugs Inhibit the Interactions between
Misfolded SOD1 Molecules Leading to
Formation of Insoluble Aggregates
We first supposed that the drugs might prevent apo-
SOD1(G37R)S-S from aggregation/oligomerization by stabilizing
its folded conformation, and we thus examined effects of
the drugs on the thermostability of apo-SOD1(G37R)S-S by
using differential scanning calorimetry (DSC). The melting
temperature, Tm, of apo-SOD1(G37R)S-S was, however,
unaffected by the drugs: 42.2◦C in the absence of any drugs; 41.6,
41.9, and 42.2◦C in the presence of simvastatin, alfacalcidol, and
miltefosine, respectively. It is thus unlikely that the drugs interact
with the folded apo-SOD1(G37R)S-S to stabilize it.
While the drugs completely suppressed the formation of
insoluble S-S oligomers, we noted that distinct, albeit slight,
amounts of disulfide cross-linked oligomers were observed also
in the soluble fraction in the presence of the drugs (Figure 4).
Furthermore, the SOD1 band around 20 kDa was blurred in the
presence of all drugs tested (indicated by arrows in Figure 4),
suggesting the disulfide shuﬄing within a SOD1 molecule
(Figure 1B). Therefore, the drugs might not act on the folded
conformation of apo-SOD1S-S so as to inhibit the disulfide
shuﬄing; rather, the drugs would prevent aberrant interactions
among the disulfide-shuﬄed SOD1s that possibly lead to the
formation of insoluble aggregates. In order to resolve those
blurred bands, the soluble fractions of apo-SOD1S-S shaken at
1200 rpm in the presence and absence of the drugs for 2 h were
examined with SDS-PAGE using a polyacrylamide gel containing
5M urea. As shown in Figure 6A, multiple bands with distinct
electrophoretic mobilities (at least four major bands) became
apparent after agitation of apo-SOD1(G37R)S-S regardless of the
presence or absence of the drugs. By treatment of the samples
with the reducing agent, DTT, the multiple bands were collapsed
into the single band corresponding to that of SOD1SH (data not
shown), corroborating that themultiplicity of bands in Figure 6A
is caused by the intramolecular disulfide shuﬄing. Given little
effects of the drugs on the band multiplicity, the drugs did not
Frontiers in Molecular Biosciences | www.frontiersin.org 6 August 2016 | Volume 3 | Article 40
Anzai et al. Inhibitors for Aggregation of SOD1
FIGURE 4 | Formation of insoluble SOD1 oligomers was efficiently suppressed by the hit compounds. As shown in Figures 2, 3, 20µM
apo-SOD1(G37R)S-S was shaken at 37◦C for 12 h in the NNE buffer containing 1MGdn in the presence of the indicated drugs (20µg/mL) and then fractionated into
soluble supernatant (s) and insoluble pellet (p) by ultracentrifugation. Both fractions were then analyzed by non-reducing SDS-PAGE using a 12.5% polyacrylamide
gel. The position of the band corresponding to SOD1 with and without the canonical disulfide bond was indicated by open and filled arrows, respectively.
TABLE 1 | Expected values for water solubility of drugs examined in this
study.
Drugs M.W.a Water solubility Data source
g/L µM
Simvastatin 418.6 7.7 × 10−4 1.8 × 100 ChemIDplusb
Lovastatin 404.5 2.1 × 10−3 5.3 × 100 ChemIDplusb
Mevastatin 390.5 4.8 × 10−3 1.2 × 101 ChemIDplusb
Pravastatin lactone 406.5 2.4 × 10−2 5.9 × 101 ChemIDplusb
Alfacalcidol 400.6 1.6 × 10−3 4.1 × 100 DrugBankc
Calcidol 400.6 2.2 × 10−3 5.5 × 100 DrugBankc
Calcitriol 416.6 6.7 × 10−3 1.6 × 101 DrugBankc
Calcipotriol 412.6 1.4 × 10−2 3.3 × 101 DrugBankc
Calciferol 396.7 4.3 × 10−4 1.1 × 100 DrugBankc
Cholecalciferol 384.6 3.8 × 10−4 1.0 × 100 DrugBankc
Miltefosine 407.6 2.2 × 10−4 5.0 × 10−1 DrugBankc
2.5 × 100 6.1 × 103 Data sheetd
aMolecular weight.
bhttp://chem.sis.nlm.nih.gov/chemidplus/.
chttp://www.drugbank.ca.
dhttps://www.caymanchem.com/pdfs/63280.pdf.
suppress abnormal shuﬄing of the disulfide bond within an
apo-SOD1(G37R)S-S molecule.
Shuﬄing of the disulfide bond in SOD1 proteins can be
more directly examined with a disulfide mapping analysis
using MALDI-TOF mass spectrometry followed by the limited
tryptic digestion. In the absence of Gdn, tryptic digestion of
apo-SOD1(G37R)S-S produced mass peaks at m/z 4350 and
4507, which correspond to the peptides containing the canonical
disulfide bond between Cys 57 and Cys 146 (Figure 6B, w/o
Gdn). In contrast, several other mass peaks were emerged at m/z
4038 and 4607, when the apo-SOD1(G37R)S-S sample agitated
in the presence of 1MGdn was trypsinized (Figure 6B, no
drugs). These mass peaks correspond to the peptides containing
abnormal disulfide bonds between Cys 6 and Cys 57 (m/z 4038)
and between Cys 111 and Cys 146 (m/z 4607), consistent with the
shuﬄing of the disulfide bond. These four mass peaks observed
at m/z 4038, 4350, 4507, and 4607 disappeared upon treatment
of the samples with DTT before the measurement (data not
shown), supporting that the observed mass peaks represent the
peptides crosslinked via an intramolecular disulfide bond(s). In
the presence of the drugs, nonetheless, the mass peaks of those
peptides containing abnormal disulfide bonds were still observed
(Figure 6B), confirming that the drugs were unable to suppress
the disulfide shuﬄing process within a SOD1 molecule.
The drugs we found here can almost completely suppress
the formation of insoluble SOD1 aggregates cross-linked via
disulfide bonds. The drugs were not able to inhibit the
disulfide shuﬄing within a SOD1 molecule but could act on
the soluble disulfide-shuﬄed SOD1 molecules to stop further
aggregation into the insoluble species (Figure 6C). Soluble SOD1
oligomers have been shown to exhibit significant toxicities
toward cultured cells (Luchinat et al., 2014; Proctor et al.,
2016), while identities of the soluble oligomers in the previous
studies would not match those of soluble disulfide-shuﬄed SOD1
in our current study. Actually, it remains obscure whether
the misfolded SOD1 with an intramolecularly-shuﬄed disulfide
bond is monomeric, dimeric, or oligomeric. Potential toxicities
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FIGURE 5 | Specificity of the hit compounds for the inhibition of apo-SOD1(G37R)S-S oligomerization. (A) 20µM apo-SOD1(G37R)SH in the NNE buffer
with 5mM DTT was shaken at 1200 rpm at 37◦C in the presence or absence of the indicated drugs (20µg/mL). After 24 h of agitation, the samples were fractionated
to soluble supernatant (s) and insoluble pellets (p) by ultracentrifugation and then analyzed by non-reducing SDS-PAGE using a 12.5% polyacrylamide gel. (B) Effects
of the drugs (20µg/mL) on the aggregation kinetics of 20µM HTTEX1(42Q) were monitored by solution turbidity (absorbance at 350 nm): no drugs (filled circles),
alfacalcidol (open circles), miltefosine (open triangles), and simvastatin (open squares).
of the soluble SOD1 species with a shuﬄed disulfide bond
will also need to be examined, and our drugs might aggravate
but not ameliorate the disease symptoms by stabilizing the
soluble misfolded SOD1. Nonetheless, insoluble S-S oligomers
are also observed as pathological species in the ALS-model mice;
therefore, the drugs modulating the pathway for the formation
of S-S oligomers will give pharmacological insights into the
pathogenesis of SOD1-ALS.
Caveats for the Development of
Pharmaceuticals for SOD1-ALS Based
upon the Drugs Found in This Study
Among the drugs reported here, statins have been reported to
associate with the occurrence of neuromuscular degenerative
disease and an ALS-like syndrome, albeit controversial (Edwards
et al., 2007; Sorensen and Lash, 2009; Zheng et al., 2013).
Actually, prescription of statins for men and women in their 60 s
dramatically increased from 1991 to 1998 (Magrini et al., 1997;
Riahi et al., 2001), but no similar increase of ALS incidence was
observed (Fang et al., 2009). Side effects of statin medications
include muscle toxicity such as myopathy (Sathasivam and
Lecky, 2008), and limited evidence for neurotoxic effects of
statins has been reported (Kiortsis et al., 2007). Nonetheless,
a strong association between statin medications and functional
decline/muscle cramping in patients with ALS has been reported
(Zinman et al., 2008). While it remains unknown if statins are
beneficial for ALS patients with SOD1mutations, administration
of the statin (simvastatin) to SOD1-ALS model mice expressing
human SOD1 with G93A mutation (G93A mice) was found to
accelerate the disease progression and shorten the survival (Su
et al., 2016). Given that a high level of lipids in serum is also
proposed to be neuroprotective in ALS cases (Dupuis et al.,
2008; Yoshii et al., 2010), treatment of ALS patients with statins
inhibiting the biosynthesis of cholesterol should be cautious.
In contrast, vitamin D has been proposed as a potential
therapy in ALS (Gianforcaro and Hamadeh, 2014), and several
mechanisms describing positive effects of vitamin D on ALS
have been suggested (Gianforcaro and Hamadeh, 2014). Among
those, supplementation of vitamin D has been found to decrease
the levels of pro-inflammatory cytokines such as TNF-α and
would thereby reduce neuroinflammation in ALS (Gianforcaro
and Hamadeh, 2014). Also, vitamin D has been suggested to have
roles in muscle cell proliferation and differentiation and thus
improve musculoskeletal functions (Gianforcaro and Hamadeh,
2014); indeed, vitamin D3 supplementation to the ALS patients
reduced their decline in the ALSFRS-R score (Karam et al., 2013),
which is a functional rating scale, and levels of vitamin D (serum
calcidiol) appear to correlate with the ALS prognosis (Camu
et al., 2014). Furthermore, vitamin D receptor-knockout mice
exhibited significant impairment of locomotor and muscular
functions, supporting a role of vitamin D in the maintenance
of motor neurons (Burne et al., 2005). Deficiency of vitamin D3
in G93A mice was found to improve early disease severity and
delays disease onset but with decline in the motor performance
(Solomon et al., 2011); instead, supplementation of high doses of
vitamin D3 to G93A mice improved their paw grip endurance
and motor performance but with limited effectiveness on the
disease course (Gianforcaro and Hamadeh, 2012; Gianforcaro
et al., 2013). It is thus interesting to test in the future if vitamin D
and/or its derivatives interact with mutant SOD1 to suppress the
misfolding process and reduce their neurotoxicity in model mice.
Miltefosine is an antimicrobial drug that exhibits activity
against parasites, pathogenic bacteria, and fungi (Dorlo
et al., 2012), while no reports have been published on
its efficacy to ALS and other neurodegenerative diseases.
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FIGURE 6 | The drugs could not inhibit the disulfide shuffling within an apo-SOD1(G37R)S-S molecule. (A) Apo-SOD1(G37R)S-S (20µM) was agitated for
2 h in the presence of 1MGdn with and without the indicated drugs, and the soluble fraction obtained with ultracentrifugation was analyzed by non-reducing
SDS-PAGE using a 12.5% polyacrylamide gel in the presence of 5M urea. As controls, SOD1SH and SOD1S-S were also loaded on a gel. (B) After agitated for 2 h at
37◦C in the presence of 1MGdn, the soluble fractions of apo-SOD1(G37R)S-S were trypsinized and analyzed by MALDI-TOF mass spectrometry (see Materials and
methods). Reductant-sensitive mass peaks observed at m/z 4038, 4350, 4507, and 4607 were assigned to the peptides containing a disulfide bond between Cys 6
and Cys57, Cys 57 and Cys 146, Cys 57 and Cys 146, and Cys 111 and Cys 146, respectively. (C) Schematic representation of the SOD1 aggregation pathway
inhibited by the drugs. Conformational destabilization of apo-SOD1S-S triggers the intramolecular shuffling of the disulfide bond, and the drugs in this study are
considered to interact with the disulfide-shuffled conformation of SOD1 and suppress the interaction of those disulfide-shuffled SOD1 proteins that leads to the
formation of insoluble aggregates.
As summarized in the PubChem compound database
(http://pubchem.ncbi.nlm.nih.gov), miltefosine has been
reported to show toxicity toward some of human cells such
as cancer cells, macrophages, and erythrocytes; therefore, a
potential toxicity of miltefosine against neurons should be
evaluated.
While the drugs found here (statins, vitamin D derivatives,
and miltefosine) cannot be directly used for clinical treatment
of SOD1-ALS, those drugs are found to specifically interact
with a misfolded conformation of mutant SOD1 and thereby
suppress the formation of insoluble oligomers/aggregates in
vitro (Figure 6C). More effective and safer compounds with
the ability to suppress the aggregation of SOD1 could hence
be developed based upon our drugs and also be useful in
evaluating the toxicity of misfolded/aggregated SOD1 in cultured
cells to eventually modulate the disease course of SOD1-ALS
cases.
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